OptimizeRx (OPRX) Q2 FY26 earnings call

OptimizeRx delivered strong profitability and cash flow in Q2 FY26, exceeding adjusted EBITDA consensus, despite a 30% year-over-year revenue decline attributed to specific large customer dynamics and a strategic shift away from lower-margin services. The company reiterated its full-year guidance, confident in its product innovation, expanding client base outside the top 20, and disciplined expense management. Strategic investments in AI-enabled platforms and programmatic integrations are positioning OptimizeRx as a core operating system for pharmaceutical marketers, expanding its addressable